Alzheimer's Disease

Alzheimer's disease is a progressive brain disease that gradually destroys memory, thinking, language, and the ability to carry out everyday tasks. It is the most common cause of dementia, responsible for an estimated 60 to 80 percent of all dementia cases worldwide, making it the leading cause of cognitive disability in older adults. Although age is the strongest risk factor, Alzheimer's is not a normal part of aging; it is a specific disease process driven by the accumulation of abnormal proteins in the brain.

The illness develops silently for years before symptoms appear. By the time memory complaints first emerge, the underlying changes — amyloid plaques and tau tangles — have already been forming for a decade or more. Modern biomarker testing has reshaped how clinicians think about Alzheimer's: rather than waiting for severe symptoms, the disease can now be identified at a preclinical or very mild stage in many patients. This shift opens the door to earlier interventions and to a more honest conversation with families about what lies ahead.

Understanding Alzheimer's Disease

A Disease, Not Aging

Mild forgetting of names or where one placed the keys is a near-universal experience of aging and does not indicate Alzheimer's. The disease is something fundamentally different: a relentless biological process in which neurons in the hippocampus and surrounding cortex die over years, eventually spreading throughout the brain. The hallmark early symptom is the loss of recent memory — not the occasional lapse, but a true inability to encode new information so that the same conversation may be repeated minutes apart with no recollection of the earlier exchange.

Calling Alzheimer's "senility" or "just old age" obscures the medical reality and delays appropriate evaluation. While advancing years remain the single largest demographic risk factor, the majority of people over 85 do not have Alzheimer's, and many who develop the disease are in their 60s or even 50s in early-onset variants.

The Pathology Underneath

Two abnormal protein deposits define Alzheimer's at the microscopic level. The first is amyloid-beta plaques, dense clumps of misfolded peptide that accumulate between neurons. The second is neurofibrillary tangles, twisted fibers of hyperphosphorylated tau protein that form inside neurons and disrupt their internal transport systems. Together with widespread neuroinflammation and synaptic loss, these changes lead to the gradual death of cells in regions critical for memory and cognition.

The temporal order of changes is important. Amyloid accumulation appears to begin first, often fifteen to twenty years before symptoms. Tau pathology follows, and once tau spreads beyond the medial temporal lobe, clinical symptoms tend to emerge and progress. This sequence is the basis for current biomarker testing and for therapies that target amyloid early in the disease.

Early-Onset and Genetic Forms

About 5 percent of cases occur before age 65 and are referred to as early-onset Alzheimer's disease. A small subset — perhaps 1 percent of all cases — is caused by autosomal dominant mutations in the APP, PSEN1, or PSEN2 genes, which guarantee the development of the disease, often in the 30s or 40s. These familial forms have been crucial to understanding the role of amyloid in the broader population.

Who Develops Alzheimer's

• Adults over 65, with risk rising sharply with each subsequent decade
• Women, who account for nearly two-thirds of cases (partly explained by longevity)
• People with one or two APOE ε4 alleles
• Those with a first-degree relative with Alzheimer's
• Adults with Down syndrome, who develop Alzheimer's pathology nearly universally by age 60
• Individuals with poorly controlled cardiovascular risk factors
• People with prolonged untreated hearing loss, low educational attainment, or chronic social isolation

DSM-5-TR Diagnostic Criteria

The DSM-5 (2013), and its 2022 text revision the DSM-5-TR, replaced the older term "dementia" with two umbrella categories — Major Neurocognitive Disorder and Mild Neurocognitive Disorder — each of which can be specified as due to Alzheimer's disease.

Major Neurocognitive Disorder Due to Alzheimer's Disease

The diagnosis requires evidence of significant decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition). The decline must interfere with independence in everyday activities, must not occur exclusively during delirium, and must not be better explained by another mental disorder.

To specify the Alzheimer's etiology, clinicians look for insidious onset and gradual progression of impairment in at least two cognitive domains, and either a causative genetic mutation (probable) or a clinical course of steady decline without clear evidence of mixed etiology (probable vs. possible).

Mild Neurocognitive Disorder Due to Alzheimer's Disease

This category captures the stage formerly called mild cognitive impairment of the Alzheimer type. There is a modest decline in cognition that is greater than expected for age but does not yet impair functional independence. Compensatory strategies and extra effort may be needed for complex tasks, but daily life can still be managed.

Specifiers

• With or without behavioral disturbance: Documenting psychotic features, mood disturbance, agitation, apathy, or other behavioral symptoms
• Severity (for Major NCD): Mild (difficulties with instrumental activities of daily living), moderate (difficulties with basic activities), or severe (fully dependent)

Biomarker-Supported Diagnosis

Newer research frameworks, including the NIA-AA criteria, define Alzheimer's biologically by the presence of amyloid and tau biomarkers regardless of symptoms. This is reshaping clinical practice: a person with positive amyloid PET and tau pathology is considered to have Alzheimer's disease even if cognitive change is subtle, while a person with classic dementia symptoms but negative amyloid biomarkers likely has a different underlying cause.

Stages and Disease Course

Preclinical Alzheimer's

In this earliest phase, amyloid and sometimes tau pathology are present in the brain but cognition appears normal on standard testing. Sensitive measures may detect very subtle changes. This stage can last a decade or longer and is the focus of secondary prevention research aimed at intervening before symptoms emerge.

Mild Cognitive Impairment Due to Alzheimer's

Memory difficulties become noticeable to the person and to those close to them. Appointments are missed, the same questions are asked repeatedly, and previously easy tasks now require lists or reminders. Independence is preserved, but cognitive effort increases. In clinic-based studies, roughly 10 to 15 percent of people with mild cognitive impairment progress to dementia each year, and the risk is higher when Alzheimer's biomarkers are positive. Our guide to mild cognitive impairment explains this stage in more detail.

Mild Dementia

Memory loss is now consistent and noticeable to others. Word-finding difficulty becomes more frequent. Driving may become unsafe in unfamiliar areas. Managing finances, medications, or appointments without help becomes difficult. Personality may shift toward greater anxiety, suspicion, or withdrawal. Most people are still able to live at home with support.

Moderate Dementia

Help is needed for basic daily activities such as dressing, bathing, and meal preparation. Memory now affects long-held information, not just recent events. The person may become disoriented in familiar surroundings, fail to recognize less-frequently-seen relatives, and have difficulty following conversations. Behavioral symptoms such as agitation, wandering, sleep disruption, and hallucinations are common. Caregiver burden rises sharply.

Severe Dementia

Communication becomes limited to single words or facial expressions. Mobility declines, with eventual loss of the ability to walk, sit unsupported, or swallow safely. Continence is lost. Recognition of even close family members fades. Care needs are total. Death usually results from pneumonia, urinary infection, or other complications of immobility and frailty rather than from the brain disease directly.

Trajectory and Variability

The average time from diagnosis to death is 8 to 12 years, but the range is wide. Some people progress rapidly over three to four years; others stabilize at a mild stage for many years. Younger age at onset, APOE ε4 homozygosity, vascular comorbidity, and certain atypical presentations are associated with faster decline.

Symptoms and Warning Signs

Memory Symptoms

• Repeating the same question or story within a short time, unaware of having done so
• Forgetting recent events, conversations, and appointments while remembering distant ones
• Losing items in unusual places and being unable to retrace steps
• Increasing reliance on family members or notes to track daily life
• Forgetting names of acquaintances or, later, close family

Language and Communication

• Difficulty finding the right word, with use of vague substitutes like "thing" or "that one"
• Trouble following or contributing to a multi-person conversation
• Reading comprehension that fades after a paragraph or two
• Reduced spontaneous speech and storytelling

Visuospatial Problems

• Getting lost while driving in familiar areas or walking in one's own neighborhood
• Trouble judging distance, leading to bumping into objects or near-misses while driving
• Difficulty interpreting diagrams, maps, or even photographs
• Posterior cortical atrophy, a visual variant, may present primarily with these symptoms before memory loss

Executive Function

• Trouble managing finances — unpaid bills, duplicate payments, susceptibility to scams
• Difficulty planning multi-step activities like cooking a meal
• Reduced ability to adapt when plans change
• Slowed and effortful problem-solving

Behavioral and Psychiatric Symptoms

• Apathy and loss of interest in formerly enjoyed activities
• Depression and anxiety, sometimes preceding cognitive symptoms
• Suspicion or paranoia, often centered on missing items being "stolen"
• Agitation, restlessness, or pacing
• Sleep-wake cycle disruption, with day-night reversal in advanced disease
• Sundowning — increased confusion and restlessness in late afternoon and evening

What Alzheimer's Is Not

Knowing the date but momentarily forgetting it, occasionally losing keys, or struggling to recall an actor's name does not indicate the disease. Likewise, sudden and stepwise changes, abrupt confusion over hours, or the appearance of vivid visual hallucinations early in the course point away from typical Alzheimer's and toward delirium, vascular dementia, or Lewy body disease. Ordinary age-related changes are covered in our guide to cognitive decline.

Causes and Risk Factors

Age

Age is the single strongest predictor of Alzheimer's. Alzheimer's Association estimates for the US put prevalence at about 5 percent of people aged 65–74, about 13 percent at ages 75–84, and roughly one in three adults aged 85 and older. The cumulative effect of cellular aging, vascular changes, and reduced clearance of amyloid all contribute.

Genetics

Beyond the rare autosomal dominant mutations, the most important genetic factor is the APOE gene on chromosome 19. The APOE ε4 allele increases risk and lowers the age of onset, while the ε2 allele appears protective. Heterozygotes for ε4 have roughly three times the risk; homozygotes have eight to twelve times the risk and earlier onset. Polygenic risk scores combining many smaller variants add modest additional predictive power but are not used routinely in clinical practice.

Cardiovascular and Metabolic Risk

• Midlife hypertension (especially untreated systolic above 140)
• Diabetes mellitus and insulin resistance
• Midlife obesity
• High LDL cholesterol
• Smoking
• Physical inactivity

These factors influence both classic Alzheimer's pathology and the vascular contribution to mixed dementia, which is extremely common in older adults.

Lifestyle and Environmental Risk

The Lancet Commission on dementia prevention identified twelve potentially modifiable risk factors in 2020 and added two more, untreated vision loss and high LDL cholesterol, in its 2024 update. Together these 14 factors are estimated to account for about 45 percent of dementia cases worldwide: less education in early life; midlife hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, hypertension, obesity, and excessive alcohol use; and later-life social isolation, air pollution, and untreated vision loss. These are population-level estimates based largely on observational data, so they show where prevention efforts could help rather than guaranteeing that any one change will prevent the disease for an individual.

Hearing loss is particularly notable. Observational studies link hearing aid use to lower rates of cognitive decline, and the 2023 ACHIEVE trial found that a hearing intervention slowed decline in a subgroup of older adults at higher risk, though not in the full study sample.

Head Injury

A history of moderate to severe traumatic brain injury, especially with loss of consciousness, increases the risk of later neurocognitive disorders. Repeated mild concussions, as seen in some contact sports and military service, are associated with chronic traumatic encephalopathy and may also raise the risk of Alzheimer's-type pathology.

Mental and Social Engagement

Education and lifelong cognitive engagement contribute to cognitive reserve — the brain's ability to compensate for pathology before symptoms appear. Social engagement, novel learning, and meaningful work are associated with later onset of clinical symptoms even in the presence of significant brain pathology.

Sleep

Chronic short sleep and untreated obstructive sleep apnea are linked with higher amyloid burden. Deep sleep appears to support the glymphatic clearance of metabolic waste, including amyloid, from the brain. Treating sleep apnea is increasingly recognized as part of comprehensive brain health.

Medical Complications

Falls and Fractures

Impaired judgment, gait disturbance, and visuospatial problems sharply raise fall risk. Hip fractures and head injuries in this population carry high morbidity, often accelerating cognitive decline and shortening life expectancy.

Weight Loss and Malnutrition

As the disease progresses, people may forget to eat, lose appetite, or have difficulty using utensils. In later stages, dysphagia (impaired swallowing) raises the risk of aspiration. Weight loss and sarcopenia are common in moderate and severe stages and require attention from caregivers and clinicians.

Aspiration Pneumonia

Aspiration of food, fluid, or oral secretions into the lungs becomes a frequent cause of acute illness in advanced disease and is the most common immediate cause of death. Swallow evaluation, careful feeding posture, and texture-modified diets can help, though feeding tubes have not been shown to extend life or improve comfort in advanced dementia.

Infections and Delirium

Urinary tract and respiratory infections in someone with Alzheimer's frequently provoke acute confusion that exceeds baseline impairment. Each episode of delirium can leave residual cognitive decline; preventing and rapidly treating infections is therefore particularly important.

Pressure Injuries and Immobility

Loss of mobility in late disease leads to pressure injuries, deep vein thrombosis, and contractures. Repositioning schedules and skin care are part of palliative care.

Depression and Suicidality

Depression is common at every stage. Awareness of decline, loss of independence, and social withdrawal contribute. Suicidality, while less common than in younger psychiatric populations, is not negligible and warrants screening, especially around the time of diagnosis.

Caregiver Health

Although not a complication in the person with Alzheimer's, deterioration in caregiver physical and mental health is a recognized public health concern. Burnout, depression, and chronic medical illness occur at elevated rates in family caregivers and feed back into the quality of patient care.

Assessment and Diagnosis

Clinical Interview

Diagnosis begins with a detailed history from both the patient and a knowledgeable informant. Onset, tempo of change, specific cognitive domains affected, functional consequences, mood, sleep, medications, and vascular history are explored. The informant interview is essential because patients often have limited insight into their own changes.

Cognitive Screening and Neuropsychological Testing

• MMSE (Mini-Mental State Examination): A 30-point screen, useful but insensitive to mild impairment and influenced by education
• MoCA (Montreal Cognitive Assessment): A 30-point screen more sensitive to mild impairment and to executive deficits
• Mini-Cog: Brief three-word recall plus clock drawing
• Full neuropsychological battery: Reserved for unclear cases, atypical presentations, or younger patients where domain-specific profiling guides differential diagnosis

Laboratory Workup

Standard labs screen for reversible contributors to cognitive impairment and include complete blood count, comprehensive metabolic panel, thyroid function, vitamin B12, and sometimes folate. HIV and syphilis testing are considered when risk factors or clinical features suggest infection.

Brain Imaging

• MRI or CT: Used to exclude tumors, hematomas, hydrocephalus, and large strokes, and to demonstrate hippocampal and medial temporal atrophy typical of Alzheimer's
• FDG-PET: Shows characteristic temporoparietal hypometabolism in Alzheimer's
• Amyloid PET: Visualizes amyloid plaque burden; a negative scan effectively rules out Alzheimer's as the cause of cognitive symptoms
• Tau PET: Visualizes tau deposition and correlates with clinical severity

Cerebrospinal Fluid Biomarkers

Lumbar puncture allows measurement of amyloid-beta 42, total tau, and phosphorylated tau (p-tau 181 or 217). A profile of low amyloid-beta 42 and elevated p-tau supports the diagnosis of Alzheimer's pathology with high accuracy.

Blood-Based Biomarkers

Plasma p-tau 217 and related markers have emerged in recent years as accurate, less invasive ways to detect Alzheimer's pathology. As these assays become widely available, they are likely to transform early diagnosis, particularly in primary care, by identifying who should proceed to confirmatory PET imaging or CSF testing.

Differential Diagnosis

• Vascular dementia or mixed vascular-Alzheimer's pathology
• Dementia with Lewy bodies and Parkinson's disease dementia
• Frontotemporal dementias (behavioral variant and primary progressive aphasias)
• Normal pressure hydrocephalus
• Depression-related pseudodementia
• Medication-induced cognitive impairment, especially anticholinergics, benzodiazepines, and sedatives
• Untreated sleep apnea, thyroid disease, or B12 deficiency

Treatment Approaches

Symptomatic Medications

Two long-established classes of medication are used to ease symptoms. Cholinesterase inhibitors slow the breakdown of acetylcholine, a chemical messenger involved in memory that is depleted in Alzheimer's. An NMDA receptor antagonist acts on the glutamate system and is used in moderate to severe disease. Research shows that these medications produce modest symptomatic benefit for some people, often for a limited period, but they do not stop the underlying disease. Whether they are appropriate, and how side effects are monitored, is a decision made with a prescribing doctor.

Anti-Amyloid Antibodies

Monoclonal antibodies that bind and clear amyloid plaques are the first treatments shown to modify the course of Alzheimer's. The first of these received accelerated US approval in 2021 but was discontinued in 2024 amid questions about its clinical benefit. Two others received full FDA approval in 2023 and 2024 after large trials showed modest slowing of decline, roughly a quarter to a third on some trial measures over 18 months, in people with mild cognitive impairment or mild dementia and confirmed amyloid pathology. Experts continue to debate whether a slowing of that size is noticeable in daily life.

The treatments carry meaningful risks. Amyloid-related imaging abnormalities (ARIA), including brain edema and microhemorrhages, occur in a sizable minority of treated patients, especially APOE ε4 homozygotes. Serial MRI monitoring is required. Treatment involves regular infusions, and eligibility is restricted to people with early-stage disease and confirmed amyloid biomarkers. Some health systems outside the US have declined to fund these drugs because of the balance of modest benefit, risk and cost. Weighing expected benefit, risk, monitoring burden, and cost is a conversation for the person, their family, and specialist doctors.

Treatment of Behavioral and Psychological Symptoms

Nonpharmacological strategies are first-line and include identifying and addressing triggers (pain, infection, constipation, hunger, fear, overstimulation), establishing consistent routines, modifying the environment, and using validation and reassurance rather than confrontation with reality. Caregiver education is itself a powerful intervention. Approaches drawn from geriatric mental health care also address the anxiety and low mood that often accompany diagnosis.

Medication is sometimes considered when symptoms such as severe distress, depression, agitation or psychosis do not respond to these approaches or pose safety risks. Several medicines that act on the brain carry significant risks for older adults with dementia, including increased risk of falls, confusion and, for some classes, higher mortality, which is why clinical guidelines emphasize careful specialist review. Families can ask the care team to explain the purpose, risks and review plan for any medication.

Lifestyle and Multimodal Prevention

The FINGER trial demonstrated that a multidomain intervention — diet, exercise, cognitive training, and vascular risk monitoring — improved cognition in older adults at risk for dementia. Subsequent international trials are replicating and extending these findings. Mediterranean-style or MIND diets, regular aerobic and resistance exercise, smoking cessation, blood pressure control, treatment of hearing loss, social engagement, and consistent sleep all contribute to brain health and may meaningfully delay onset.

Cognitive Rehabilitation and Stimulation

Cognitive stimulation therapy — structured group activities targeting different cognitive domains — has modest evidence for improving quality of life and cognition in mild to moderate dementia. Individualized cognitive rehabilitation, focused on personally meaningful goals, can support continued independence in early disease.

Advance Care Planning

Because Alzheimer's eventually impairs decision-making, early conversations about advance directives, durable power of attorney for healthcare and finances, preferences regarding hospitalization, life-prolonging measures, tube feeding, and end-of-life care are essential. Decisions made while the person can still participate honor their values and prevent crises later. Palliative care principles apply across the trajectory, and hospice is appropriate in late-stage disease.

Living With Alzheimer's and Caregiving

For the Person With a Diagnosis

A diagnosis of Alzheimer's is a major life event, but it is not the same as immediate incapacity. Many people live meaningfully for years with mild disease. Practical steps include simplifying schedules, using a single calendar and notebook system, setting up automatic bill payment, maintaining physical activity and social ties, addressing hearing and vision, and ensuring sleep quality. Discussing the diagnosis with family early avoids confusion later and allows shared planning.

Driving

Driving safety needs to be reassessed periodically. Subtle warning signs include getting lost, near-misses, slowed reactions, or a recent crash. Comprehensive driving evaluations through occupational therapy programs can provide objective guidance. Loss of driving privileges is one of the most emotionally difficult transitions and benefits from compassionate but firm planning, with alternative transportation arranged in advance.

Home Safety

• Remove tripping hazards, secure rugs, and improve lighting
• Install grab bars in bathrooms and consider a shower seat
• Adjust water heater temperature to prevent scalds
• Lock away firearms, hazardous chemicals, and unused medications
• Use stove safety devices or shutoffs as cooking becomes risky
• Consider GPS tracking or identification bracelets for those at risk of wandering

Communication Strategies

• Speak clearly, slowly, and one idea at a time
• Limit choices to two options to reduce overwhelm
• Use the person's name and identify yourself when needed
• Reduce background noise during conversation
• Validate emotions rather than correcting factual errors
• Redirect rather than argue when a person is fixed on a false belief

For Family Caregivers

Caregiving for someone with Alzheimer's is one of the most demanding roles in medicine and family life. Burnout, depression, sleep deprivation, and worsening physical health are all common (see our guide to caregiving). Sustainable caregiving usually involves:

• Accepting help — from family, friends, paid aides, and adult day programs
• Joining a caregiver support group, in person or online
• Maintaining one's own healthcare appointments and physical activity
• Using respite services regularly, not only in crisis
• Planning for transitions of care, including residential memory care when needed

End-of-Life Considerations

In late-stage disease, the focus shifts to comfort, dignity, and presence. Hospice care provides expert symptom management, family support, and bereavement services. Decisions about hospitalization, antibiotics for recurrent infections, and feeding all benefit from honest conversations grounded in the person's previously expressed values. A peaceful death at home or in a familiar setting is often achievable with adequate planning.

When to Seek Help

Concerning Cognitive Changes

Evaluation is warranted when memory or thinking changes are noticed by the person, by family members, or by colleagues — particularly when they are persistent, progressive, or affecting daily life. Early evaluation can uncover reversible contributors, establish a baseline, and access treatments that work best when started early. Waiting "to see if it gets worse" sacrifices time when intervention is most effective.

Red-Flag Symptoms

• Sudden onset of confusion (consider delirium, stroke, infection)
• Rapid progression over weeks rather than years (consider prion disease, autoimmune encephalitis, malignancy)
• Prominent early hallucinations or parkinsonism (consider Lewy body disease)
• Early personality change, disinhibition, or language disturbance (consider frontotemporal dementia)
• Gait disturbance with urinary incontinence (consider normal pressure hydrocephalus)
• New severe headache, seizures, or focal weakness (urgent imaging)

Mood and Safety Concerns

Depression, hopelessness, talk of being a burden, or any expression of suicidal thought deserves prompt clinical attention. Risk is highest around the time of diagnosis and during major transitions such as loss of driving or move to residential care.

Where to Start

• Primary care physician for initial workup and referral
• Neurologist, geriatrician, geriatric psychiatrist, or memory clinic for specialized evaluation
• Neuropsychologist for detailed cognitive testing in unclear or atypical cases (see neuropsychological testing)
• Alzheimer's Association local chapter for education, support groups, and community resources

Conclusion

Alzheimer's disease is a specific, biological, progressive illness of the brain, not a natural part of getting older. Decades of research have clarified its pathology, identified powerful risk factors that can be modified, and produced the first generation of disease-modifying treatments. While there is no cure, the situation in 2026 is very different from that of even ten years ago: amyloid and tau can be measured noninvasively, early intervention is possible, and a meaningful portion of dementia risk in the population is preventable.

Care still rests on more than medications. The combination of accurate diagnosis, attention to cardiovascular and metabolic health, treatment of sensory loss, structured daily routines, social and cognitive engagement, behavioral strategies for symptom management, advance planning, and steady support of family caregivers shapes outcomes far more than any single drug. People with Alzheimer's can live with purpose, connection, and dignity for years after diagnosis when these elements are in place.

If you or someone you love is noticing changes in memory or thinking, the most important step is to seek evaluation rather than to wait. The earlier the cause is clarified, the more options are available — to slow the disease, to address reversible contributors, to plan for the future, and to gather a team that will walk the journey with you. Alzheimer's is hard, but it does not have to be faced alone.